Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
Scholar Rock’s myostatin blocker has shown its efficacy in spinal muscular atrophy, and the 28-year-old myostatin field is now looking to muscle in on obesity.
Scholar Rock has submitted its anti-myostatin antibody apitegromab for FDA approval, just months after reporting that it hit its primary endpoint in phase III for spinal muscular atrophy (SMA). Approval would upend two decades of failure for myostatin pathway inhibitors, a class of drugs that grows skeletal muscle. Beyond the first regulatory decision for apitegromab, companies are pivoting to the larger potential medical and commercial opportunity for muscle mass preservation in overweight and obese individuals taking the wildly popular incretin mimetic weight-loss drugs.
